Revlimid, Imnovid combos receive EU approval

The European Commission has approved two of Celgene’s combination regimens involving Revlimid (lenalidomide) and Imnovid (pomalidomide). The first, Revlimid in combination with bortezomib and dexamethasone (RVd) is for the indication of adult patients with previously untreated multiple myeloma who are not eligible for transplant. The second combo is Imnovid in combination with bortezomib and dexamethasone (PVd), in adult patients with multiple myeloma, who have received at least one prior treatment regimen including Revlimid. The approval for the Revlimid triplet (RVd) was supported by data from SWOG S0777 phase III trial evaluating the combination, RVd, in adult patients with previously untreated multiple myeloma. The approval of the Imnovid triplet (PVd) was supported by data from OPTIMISMM phase III trial to evaluate an Imnovid-based triplet regimen in patients who were all previously treated with Revlimid.